thymosin beta-4 fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Most of the deductions investigated by the operation could have begun as early as 2016 (the last year of the Dilma Roussef government), with many of them also continuing through the presidencies of Michel Temer and Bolsonaro; some deductions were even reported to be occurring up until 2024 (the second year of Lula's administration), when the scheme was first reported to the CGU. The entity that received the most values transferred by the INSS was the National Confederation of Workers in Agriculture (CONTAG), suspected by the PF of diverting 2 billion reais from retirees and pensioners since 2019. One of the entities involved, the National Union of Retirees, Pensioners and the Elderly, has as its vice president Lula's brother José Ferreira da Silva (also known as Frei Chico), who had previously been investigated in Operation Car Wash. Despite warnings made by an INSS advisor as early as 2023 to the Minister of Social Security, Carlos Lupi, no concrete measures were adopted to curb the fraudulent deductions. By judicial decision, the president of the INSS, Alessandro Stefanutto, appointed in July 2023 in place of Glauco Wamburg, who was serving as interim president of the institution, was removed from the exercise of the function, along with other INSS authorities. Subsequently, after the removal, they were dismissed by Lula.
Since their construction and decoration between the 4th and 8th centuries CE, the Kizil Caves have suffered numerous periods of religious vandalism and decay. Western archaeologists orchestrated the massive sampling on the best remaining works of art in the early 20th century. Aside from their colonial outlook, one of their alleged motivations was to protect these works of arts from vandalism due to Islamic iconoclasm and the depredations of treasure hunters. Most of the dismantled panels were sent to the Museum für Indische Kunst, Berlin, Germany, but many were destroyed in World War II, with only photographs or drawings remaining in the best cases. A significant number of the murals were also captured by the Soviets in Berlin, and turned up recently in the Hermitage Museum. In more recent times, the Red Guards also contributed to the destruction of the site, and last but not least, the transformation of the site for touristic purposes since 2005 has led to the disfigurement of many caves and the irretrievable loss of archaeological knowledge. Today, none of the caves can be said to have remained entirely intact, although many remain quite impressive.
The Mark V initially used a single power source for the flashlight, sprinting, and oxygen supply; in Half-Life 2: Episode Two the flashlight was given a separate power source to improve gameplay. The symbol on Gordon's HEV suit is the lowercase Greek letter Lambda, λ. This symbol is used by scientists to denote the decay constant of radioactive elements (related to the half-life of an element). As well as appearing on Gordon's suit, the symbol replaces the letter "a" in the game title (Hλlf-Life) and is the name of the complex in the Black Mesa Research Facility where teleportation experiments are conducted in the first game. The Lambda symbol is also seen in Half-Life 2 as a marking of the human resistance, seen close to hidden supplies and on the armbands of better equipped resistance fighters.
In this case, the objective is the creation of chassis genomes based on necessary genes and other required DNA sequences rather than the design of metabolic or regulatory pathways based on abstract criteria.
An overview of the history was published in 2012. In 1934, the Hungarian physician Paul György discovered a substance that was able to cure a skin disease in rats (dermatitis acrodynia). He named this substance vitamin B6, as numbering of the B vitamins was chronological, and pantothenic acid had been assigned vitamin B5 in 1931. In 1938, Richard Kuhn was awarded the Nobel Prize in Chemistry for his work on carotenoids and vitamins, specifically B2 and B6. Also in 1938, Samuel Lepkovsky isolated vitamin B6 from rice bran. A year later, Stanton A. Harris and Karl August Folkers determined the structure of pyridoxine and reported success in chemical synthesis, and then in 1942 Esmond Emerson Snell developed a microbiological growth assay that led to the characterization of pyridoxamine, the aminated product of pyridoxine, and pyridoxal, the formyl derivative of pyridoxine. Further studies showed that pyridoxal, pyridoxamine, and pyridoxine have largely equal activity in animals and owe their vitamin activity to the ability of the organism to convert them into the enzymatically active form pyridoxal-5-phosphate. Following a recommendation of IUPAC-IUB in 1973, vitamin B6 is the official name for all 2-methyl,3-hydroxy,5-hydroxymethylpyridine derivatives exhibiting the biological activity of pyridoxine. Because these related compounds have the same effect, the word "pyridoxine" should not be used as a synonym for vitamin B6.
Sources: en.wikipedia.org
=== Boers retreat === The set-piece period of the war now largely gave way to a guerrilla war, but one final operation remained. President Kruger and what remained of the Transvaal government had retreated to eastern Transvaal. Roberts, joined by troops from Natal under Buller, advanced against them, and broke their last defensive position at Bergendal on 26 August. As Roberts and Buller followed up along the railway line to Komatipoort, Kruger sought asylum in Portuguese East Africa (modern Mozambique). Some dispirited Boers did likewise, and the British gathered up much war material. However, the core of the Boer fighters under Botha easily broke back through the Drakensberg Mountains into the Transvaal highveld after riding north through the bushveld. As Roberts's army occupied Pretoria, the Boer fighters in the Orange Free State retreated into the Brandwater Basin, a fertile area in the south-east of the Republic. This offered only temporary sanctuary, as the mountain passes leading to it could be occupied by the British, trapping the Boers. A force under General Archibald Hunter set out from Bloemfontein to achieve this in July 1900. The hard core of the Free State Boers under De Wet, accompanied by President Steyn, left the basin early. Those remaining fell into confusion and most failed to break out before Hunter trapped them.
=== In vivo approaches === The first direct evidence for in vivo persistence of intrinsic disorder has been achieved by in-cell NMR upon electroporation of a purified IDP and recovery of cells to an intact state. This was achieved in 2016. In vivo biotinylation was originally used to study which proteins come in the proximity of each other (proximity tagging). It was hypothesized and proven in 2018 that biotinylation favors intrinsically disordered regions as they are more accessible. Although the association between biotinylation and disorder is not absolute, the preference is strongly suggestive of a disordered state in vivo. Because biotinylation status can be checked for a large number of residues at the same time, large-scale biotin "painting" can identify many likely disordered regions at the same time.
== Simulating glycated hemoglobin (HbA1c) levels == Glycated hemoglobin (HbA1c) levels are widely regarded as a marker of medium-term blood glucose control and are extensively applied clinically as an indicator of a person's average or integrated glycemic control over the preceding 2–3 months. Diabetologists, endocrinologists, diabetes specialist nurses and diabetes educators use assessments of HbA1c levels to confirm overall blood glucose control; this test having the advantage of not being dependent on patient self-reported blood glucose data. Since the year 2000, an estimate or simulation of HbA1c levels has been incorporated within the AIDA program. This offers people with diabetes, their relatives, students, health-care professionals and other users an indication of what the HbA1c level might be if the simulated blood glucose profile was maintained for 2–3 months. The AIDA developers stress that such HbA1c level estimations, like AIDA's main blood glucose simulations, are only intended for educational / teaching, self-learning or demonstration purposes, and not meant for individual patient prediction or therapy planning.
6'-deoxychalcone synthase (EC 2.3.1.170) is an enzyme that catalyzes the synthesis of the polyketide, isoliquiritigenin, from one unit of coumaroyl-CoA and three of malonyl-CoA. The enzyme requires reduced nicotinamide adenine dinucleotide phosphate (NADPH) to activate its substrate. It is present in Glycyrrhiza echinata (Russian licorice) and other leguminous plants, where it is part of the pathway to phytoalexins such as the flavanone, liquiritigenin.
In 2002, Applied Biosystems reached revenues of US$1.6 billion for the year, and took control from Celera of the support of Celera Discovery System (CDS), a data tool to answer specific genomic and proteomic queries, involving the new genetic data field of tens of thousands of single-nucleotide polymorphisms (SNPs) within the human genome. The company developed another new tool, which combined the first ever union of triple quadrupole and ion trap technologies, in proteomics research. The database itself would remain with Celera, because of shareholder approval complications. Celera would retain responsibility for its maintenance and support to existing customers, and would receive royalties from Applied Biosystems. In 2003, Catherine Burzik joined Applied's management, from Ortho-Clinical Diagnostics. Applied developed a new tool which measured antibody/antigen binding in real-time kinetic analysis of up to 400 binding interactions simultaneously. In 2004, Mike Hunkapiller retired and Cathy Burzik replaced him as President of Applied Biosystems. Applera collaborated with General Electric, Abbott Laboratories, Seattle Genetics, and Merck in diagnostics development. Applied Biosystmes also teamed with Northrop Grumman and Cepheid of Sunnyvale, California, to detect Bacillus anthracis during the anthrax contamination case of the U.S. Postal Service. In 2005, the company released new tools for small molecule quantitation in pharmaceutical drug development.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.